<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="808">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00105105</url>
  </required_header>
  <id_info>
    <org_study_id>IA0069</org_study_id>
    <nct_id>NCT00105105</nct_id>
  </id_info>
  <brief_title>Mifepristone as Adjunctive Therapy in Alzheimer's Disease</brief_title>
  <official_title>A Double-blind, Placebo-controlled Trial of the Safety and Efficacy of C-1073 (Mifepristone) as Adjunctive Therapy in Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corcept Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute for the Study of Aging (ISOA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Aging (NIA)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of C-1073 (Mifepristone) on cognition in&#xD;
      patients with Alzheimer's disease (AD) who are also taking an acetylcholinesterase inhibitor&#xD;
      (Aricept, Exelon or Reminyl).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a double blind, placebo controlled study of C-1073 to evaluate the effects on&#xD;
      cognition in patients with mild to moderate Alzheimer's disease who are already receiving an&#xD;
      acetylcholinesterase inhibitor and have been on a stable dose for at least 12 weeks. Patients&#xD;
      will be randomized (1:1) to either daily dosing with 300 mg C-1073 or a placebo for 16 weeks.&#xD;
      Patients will continue the stable daily dose of acetylcholinesterase inhibitor throughout the&#xD;
      study.&#xD;
&#xD;
      Visits will be weekly at the beginning of the study, then every two weeks, and every 4 weeks&#xD;
      after week 12. Assessments during these visits may include cognition and behavior,&#xD;
      depression, safety, as well as physical exams, clinical laboratory tests, EKG and adverse&#xD;
      event reporting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>effects on cognition</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>effects on behavior and activities of daily living</measure>
  </secondary_outcome>
  <enrollment>160</enrollment>
  <condition>Alzheimer's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Alzheimer's disease&#xD;
&#xD;
          -  Women must have had a partial or complete hysterectomy&#xD;
&#xD;
          -  Mini Mental Status Evaluation score of 18-27&#xD;
&#xD;
          -  HAM-D score less than or equal to 18&#xD;
&#xD;
          -  Able to provide written informed consent&#xD;
&#xD;
          -  On a stable dose of an acetylcholinesterase inhibitor for at least 12 weeks prior to&#xD;
             screening visit&#xD;
&#xD;
          -  Ambulatory, or ambulatory with walker or cane&#xD;
&#xD;
          -  Sufficient hearing and vision to enable the patient to comply with the study&#xD;
             procedures&#xD;
&#xD;
          -  Caregiver available to participate in the assessment of the patient and monitor dosing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with an intact uterus&#xD;
&#xD;
          -  A clinically significant medical condition, including lab abnormality, which in the&#xD;
             opinion of the investigator would place the patient at undue risk, or would impair the&#xD;
             patient's ability to participate in the study. These include but are not limited to:&#xD;
             history of cerebral vascular accident (CVA), adrenal insufficiency, porphyrias,&#xD;
             autoimmune disorders, type I diabetes, chronic obstructive pulmonary disease (COPD),&#xD;
             hematologic or oncologic disorders in the previous 2 years, vitamin B12 or folate&#xD;
             deficiency&#xD;
&#xD;
          -  A clinically significant active gastrointestinal, renal, hepatic, endocrine, or&#xD;
             cardiovascular system disease that is not well controlled by diet, pharmacological&#xD;
             treatment, or other therapeutic intervention&#xD;
&#xD;
          -  History of psychotic episodes or bipolar disorder, or additional diagnosis of&#xD;
             delusions, delerium, or depression&#xD;
&#xD;
          -  Evidence of other psychiatric or neurologic disorders (e.g., stroke, schizophrenia, or&#xD;
             Parkinson disease)&#xD;
&#xD;
          -  Hachinski ischemia score of 5 or more&#xD;
&#xD;
          -  Known hypersensitivity to cholinesterase inhibitors&#xD;
&#xD;
          -  Use of systemic or pulmonary inhaled corticosteroids within the 30 days prior to&#xD;
             randomization, or require use of these medications during the study&#xD;
&#xD;
          -  Use of memantine (Namenda) within the 30 days prior to randomization, or require use&#xD;
             of this medication during the study&#xD;
&#xD;
          -  Currently taking medications known to significantly induce or inhibit the metabolism&#xD;
             of CYP 3A4, or have taken these medications 7 days prior to randomization (see list&#xD;
             below under prohibited medications)&#xD;
&#xD;
          -  Use of anticholinergic compounds within the 30 days prior to randomization, or require&#xD;
             use of this medication during the study&#xD;
&#xD;
          -  History of electroconvulsive therapy (ECT); patients may not undergo ECT during the&#xD;
             course of the trial&#xD;
&#xD;
          -  Positive urine drug screen for any non-prescribed drug of abuse (including but not&#xD;
             limited to amphetamines, cannabinoids, barbiturates, cocaine, opiates,&#xD;
             benzodiazepines)&#xD;
&#xD;
          -  History of illicit drugs usage or a history of drug or alcohol dependence&#xD;
&#xD;
          -  Known to have another form of dementia that may also explain the patient's deficits&#xD;
             including reversible dementias, Binswanger's, Parkinson's dementia complex,&#xD;
             Korsakoff's, mental retardation or vascular dementia. Patients who meet clinical&#xD;
             criteria for AD but who have deep white matter lesions on MRI or CT scan will be&#xD;
             accepted.&#xD;
&#xD;
          -  Currently taking prescription anticoagulants such as warfarin (Coumadin)&#xD;
&#xD;
          -  Planned surgical procedures during the study period, including the 4 week off drug&#xD;
             period between weeks 16 and 20&#xD;
&#xD;
          -  Participation in a clinical investigation of any drug, or other biological or&#xD;
             investigational therapy within 30 days prior to dosing&#xD;
&#xD;
          -  Previous participation in a trial using mifepristone, or known sensitivity or allergy&#xD;
             to C-1073 (mifepristone) or its constituents&#xD;
&#xD;
          -  Body Mass Index (BMI) over 35&#xD;
&#xD;
        Prohibited Medications:&#xD;
&#xD;
        Medications known to significantly induce or inhibit the metabolism of CYP 3A4,&#xD;
        specifically:&#xD;
&#xD;
          -  carbamazepine (Carbatrol® Tegretol®)&#xD;
&#xD;
          -  modafinil (Provigil®)&#xD;
&#xD;
          -  nefazodone (Serzone®)&#xD;
&#xD;
          -  droperidol&#xD;
&#xD;
          -  erythromycin&#xD;
&#xD;
          -  fluconazole (Diflucan®)&#xD;
&#xD;
          -  itraconazole (Sporanox®)&#xD;
&#xD;
          -  ketoconazole (Nizoral®)&#xD;
&#xD;
          -  simvastatin (Zocor®)&#xD;
&#xD;
          -  lovastatin (Mevacor®)&#xD;
&#xD;
          -  vinblastine&#xD;
&#xD;
          -  vincristine&#xD;
&#xD;
          -  paclitaxel (Taxol®)&#xD;
&#xD;
          -  tamoxifen (Nolvadex®)&#xD;
&#xD;
          -  cyclosporine (Neoral®, Sandimmune®)&#xD;
&#xD;
          -  tacrolimus (Gengraf®)&#xD;
&#xD;
          -  sirolimus (Rapamune®)&#xD;
&#xD;
          -  midazolam (Versed®)&#xD;
&#xD;
          -  nicardipine (Cardene®)&#xD;
&#xD;
          -  nifedipine (Adalat®, Procardia®)&#xD;
&#xD;
          -  felodipine (Lexxel®, Plendil®)&#xD;
&#xD;
          -  thioridizine&#xD;
&#xD;
          -  pimozide (Orap®)&#xD;
&#xD;
          -  quinidine&#xD;
&#xD;
          -  Patient may also not take St. John's Wort during the study or within 7 days prior to&#xD;
             study entry&#xD;
&#xD;
          -  the use of grapefruit juice will be excluded during the course of the study.&#xD;
&#xD;
          -  use of anticholinergic compounds over the past 30 days prior to randomization&#xD;
&#xD;
          -  warfarin (Coumadin)&#xD;
&#xD;
          -  all systemic and inhaled pulmonary corticosteroids&#xD;
&#xD;
          -  memantine (Namenda)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pivotal Research Center</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pivotal Research Center</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ATP Clinical Trials</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCI Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Neuroscience Research Medical Group, Inc.</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AVI Clinical Research</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baumel-Eisner Neuromed Inst</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baumel-Eisner Neuromed Inst</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Physiology Associates</name>
      <address>
        <city>Ft. Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baumel-Eisner Neuromed Inst</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stedman Clinical Trials</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnnie B. Byrd, Sr. Alzheimer's Center &amp; Research Inst</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memory Enhancement Center</name>
      <address>
        <city>Long Branch</city>
        <state>New Jersey</state>
        <zip>07740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastside Medical Research</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro Center of Ohio</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pahl Pharmaceutical Research, LLC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmaceutical Trials, Inc.</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research Services</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grayline Clinical Drug Trials</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Clinical Research Associates</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Clinical Research Associates</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.corcept.com</url>
    <description>Corcept Therapeutics</description>
  </link>
  <reference>
    <citation>Belanoff JK, Jurik J, Schatzberg LD, DeBattista C, Schatzberg AF. Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone. J Mol Neurosci. 2002 Aug-Oct;19(1-2):201-6.</citation>
    <PMID>12212781</PMID>
  </reference>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>March 4, 2005</study_first_submitted>
  <study_first_submitted_qc>March 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2005</study_first_posted>
  <last_update_submitted>December 10, 2009</last_update_submitted>
  <last_update_submitted_qc>December 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2009</last_update_posted>
  <keyword>Alzheimers</keyword>
  <keyword>cognition</keyword>
  <keyword>acetyl cholinesterase inhibitor</keyword>
  <keyword>GR-II antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

